The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...

Developed alongside AstraZeneca, the breakthrough designation comes following early pooled results from two ongoing trials ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated ...

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) ...

Limited (HCM) announced that the Center for Drug Evaluation of Chinas National Medical Products Administration or ...

ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. Click here to read an analysis of IBRX stock now.

The FDA approved Bizengri (zenocutuzumab-zbco) for advanced unresectable or metastatic NRG1+ NSCLC or pancreatic adenocarcinoma.

Morgan Stanley downgraded Immunocore (IMCR) to Equal Weight from Overweight with a price target of $35, down from $74. While the firm continues ...

The following is a summary of “First-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients ...

Metformin may improve lung cancer-specific clinical outcomes in obese and overweight lung cancer patients and enhance immunotherapy efficacy in this growing population as well,” researchers concluded.

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its ...